Please assess the completion status of the following clinical trial:

Trial Title: Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* High risk Ewing's Family of tumors (metastatic disease at diagnosis, humerus, femur or trunk primary, bulky primary (greater than 8 cm)), or LDH greater or equal to 900 IU/ml prior to biopsy.~* No prior chemotherapy.~* Written informed consent~* Normal cardiac function (ejection fraction greater or equal to 50%).~* Males and non pregnant females.~* Biologic age 3-60 years old.~* Adequate bone marrow function (defined as an absolute peripheral granulocyte count of\>500/mm3, platelet count of \>75,000/mm3, and hemoglobin \>8g/dl with transfusion if required).~* Adequate renal function defined as blood urea nitrogen (BUN) \<30mg% and serum creatinine \<1.5 x normal for age or creatinine clearance \>70.~* Patients of child bearing potential must agree to use an effective method of contraception.~* Normal hepatic function (bilirubin \<1.5mg/dl, serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) \<3x normal).~Exclusion Criteria: N/A

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: VACdxr With ImmTher (Type: EXPERIMENTAL): Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days. Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m\^2 IV over 1 hour every week x 50-52 weeks.
- Arm B: VACdxr (Type: ACTIVE_COMPARATOR): Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m\^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m\^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m\^2 IV daily for 2 days, Dexrazoxane 900 mg/m\^2 IV (30 minutes prior to doxorubicin).

Based on this trial design, predict the completion outcome and termination type (if applicable).